{"id":"NCT03172481","sponsor":"Purdue Pharma, Canada","briefTitle":"PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Children (6-12 Years of Age) With ADHD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-01","primaryCompletion":"2017-08-19","completion":"2017-12-19","firstPosted":"2017-06-01","resultsPosted":"2019-06-04","lastUpdate":"2019-11-05"},"enrollment":156,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ADHD"],"interventions":[{"type":"DRUG","name":"PRC-063 oral capsules","otherNames":[]},{"type":"DRUG","name":"Placebo oral capsules","otherNames":[]}],"arms":[{"label":"Active Treatment","type":"EXPERIMENTAL"},{"label":"Placebo Treatment","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric subjects between 6 to 12 years of age.","primaryOutcome":{"measure":"Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined Scores During the Full-Day Laboratory Classroom","timeFrame":"Full-day Classroom - 13 hrs","effectByArm":[{"arm":"PRC-063","deltaMin":11.4,"sd":6.9},{"arm":"Placebo","deltaMin":18.2,"sd":9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["33090921"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":74},"commonTop":["Heart Rate Increased","Sinus Tachycardia","Vomiting","Headache","Upper Respiratory Tract Infection"]}}